![[ Visit Client Website ]](images/banner.gif)
Purpose: ANCHOR-CD is a prospective, open-label, observational study of adult patients with idiopathic cervical dystonia (CD) designed to evaluate real life patient response and health economics data from patients treated with abobotulinumtoxinA (known as Dysport®). Interim efficacy (cycle one) and patient satisfaction outcomes data are reported.
Methods: Prospective, open-label, observational study of adult patients with idiopathic CD. Efficacy assessments include: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Pain Numeric Rating Scale (NRS), Clinical Global Impression of Change (CGIP), Patient Global Impression of Change (PGIC), and Treatment Satisfaction Questionnaire for Medication (TSQM).
Results: Baseline patient demographic, history, and health economic data were collected from 155 patients enrolled at 40 US clinical sites. Treated population comprised of 76% females and 24% males, mean age 58.2 years. Types of dystonic neck posturing included torticollis (81.3%), laterocollis (50.3%), retrocollis (25,8%), and anterocollis (16.1%). The median abobotulinumtoxinA dose was 500 Units. The most frequently injected muscles were the splenius capitis, levator scapulae, trapezius, semispinalis capitis, and sternocleidomastoid. Preliminary analysis included 122 patients who completed follow-up assessments for treatment cycle one. Mean (SD) TWSTRS total score was 40.3 (16.7) at baseline and 27.3 (15.5) at 4 week follow-up demonstrating -13.1 (9.2) mean change or 33% improvement compared to baseline. Mean (SD) Pain NRS score was 4.9 (3.0) at baseline and 3.6 (2.7) at 4-week follow-up demonstrating -1.4 (2.6) mean change compared to baseline. 63.9% of physicians 40.2% of patients rated much improved and very much improved for the CGIC and PGIC, respectively.
Conclusion: Physicians and cervical dystonia patients treated with abotulinumtoxinA reported improvements in the severity, disability and pain of CD.